Finally, it is notable that relatively non-selective zinc ion chelating compounds, including HDAC inhibitors such as SAHA (suberanilohydroxamic acid) (West and Johnstone, 2014), are already used for cancer treatment via S-phase targeting. The gene discussed is HDAC9; the disease is cancer.